27 August 2024 : Original article
Early Post-Transplant Serum Ferritin Levels as Predictive Biomarkers for Severe Acute Graft-Versus-Host Disease in Pediatric Umbilical Cord Blood Transplantation for Acute Leukemia
Zhiqi Zhang1ABCDEF, Bohan Li1ABCDEF, Lu Liu2ABCDEF, Ruolan Xiong1BCDE, Senlin Zhang3ABC, Minyuan Liu1ABC, Zihao Xia1BCE, Shuran Wang1BCE, Jie Li1CDEFG, Shaoyan Hu14ABCDEFG*DOI: 10.12659/AOT.944156
Ann Transplant 2024; 29:e944156
Table 1 Baseline characteristics of patients with grade 0-II and grade III–IV acute graft-versus-host disease.
| Variable | Grade 0-II aGVHD (n=53) | Grade III–IV aGVHD (n=18) | P value |
|---|---|---|---|
| 3.58 (0.67–12.57) | 3.98 (1.42–8.83) | 0.463 | |
| 0.634 | |||
| Male, n (%) | 27 (51%) | 8 (44%) | |
| Female, n (%) | 26 (49%) | 10 (56%) | |
| 0.053 | |||
| AML, n (%) | 30 (57%) | 8 (44%) | |
| ALL, n (%) | 23 (43%) | 8 (44%) | |
| MAL, n (%) | 0 (0%) | 2 (12%) | |
| 0.076 | |||
| ≥9/10, n (%) | 36 (68%) | 8 (44%) | |
| 17 (32%) | 10 (56%) | ||
| 0.663 | |||
| Matched, n (%) | 12 (23%) | 5 (28%) | |
| Mismatched, n (%) | 41 (77%) | 13 (72%) | |
| 0.405 | |||
| CR1, n (%) | 32 (60%) | 13 (72%) | |
| CR2, n (%) | 11 (21%) | 2 (11%) | |
| PR, n (%) | 7 (13%) | 3 (17%) | |
| NR, n (%) | 3 (6%) | 0 (0%) | |
| 0.037 | |||
| MAC, n (%) | 43 (81%) | 10 (56%) | |
| RIC, n (%) | 10 (19%) | 8 (44%) | |
| 0.340 | |||
| Yes, n (%) | 11 (21%) | 2 (11%) | |
| No, n (%) | 42 (79%) | 16 (89%) | |
| Bu, mg/kg | 12.31 (8.64–14.20) | 12.80 (8.40–14.10) | 0.450 |
| CTX, mg/kg | 120.00 (75.79–141.00) | 120.00 (72.00–141.18) | 0.317 |
| 15.00 (10.00–29.00) | 15.00 (12.00–23.00) | 0.680 | |
| 31.00 (13.00–43.00) | 27.50 (11.00–56.00) | 0.277 | |
| MNC, ×10/kg | 6.20 (1.30–11.33) | 5.90 (1.37–11.79) | 0.895 |
| CD34+, ×10/kg | 2.73 (1.70–6.41) | 2.78 (0.83–9.20) | 0.648 |
| 0.022 | |||
| >1650 ng/mL, n (%) | 28 (53%) | 15 (83%) | |
| 25 (47%) | 3 (17%) | ||
| 0.251 | |||
| >1650 ng/mL, n (%) | 6 (11%) | 4 (22%) | |
| 47 (89%) | 14 (78%) | ||
| aGVHD – acute graft-versus-host disease; ALL – acute lymphocytic leukemia; AML – acute myeloid leukemia; ATG – anti-thymocyte globulin; Bu – busulfan; CI – confidence interval; CR – complete response; CTX – cyclophosphamide; HR – hazard ratio; MAL – mixed phenotype acute leukemia; MNC – mononuclear cells; NR – no response; PR – partial response; SF – serum ferritin. | |||